1. Home
  2. AEYE vs GANX Comparison

AEYE vs GANX Comparison

Compare AEYE & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioEye Inc.

AEYE

AudioEye Inc.

HOLD

Current Price

$6.25

Market Cap

74.9M

Sector

Technology

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.86

Market Cap

72.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEYE
GANX
Founded
2005
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.9M
72.7M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
AEYE
GANX
Price
$6.25
$1.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$14.63
$7.50
AVG Volume (30 Days)
240.5K
725.7K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
30.56
31.46
EPS
N/A
N/A
Revenue
$40,311,000.00
$55,180.00
Revenue This Year
$11.33
N/A
Revenue Next Year
$11.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.52
N/A
52 Week Low
$5.31
$1.41
52 Week High
$16.39
$4.34

Technical Indicators

Market Signals
Indicator
AEYE
GANX
Relative Strength Index (RSI) 48.87 39.72
Support Level $5.40 $1.60
Resistance Level $9.27 $2.03
Average True Range (ATR) 0.47 0.19
MACD 0.18 -0.03
Stochastic Oscillator 47.79 10.82

Price Performance

Historical Comparison
AEYE
GANX

About AEYE AudioEye Inc.

AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: